Interleukin-6 receptor antagonists inhibit interleukin-11 biological activity

Sun Ren-Xiao, Ciliberto Gennaro, Savino Rocco, Gu Zong-Jiang, Klein . Bernard

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

The IL-6 receptor system comprises two functionally different chains: a binding chain (IL-6R) and a signal-transducing chain (gp130). The IL-6/IL-6R complexes associate with gp130, induce its dimerization and signal transduction. When IL-6 is complexed to IL-6R, two distinct sites of IL-6 are able to bind gp130. Other cytokines - oncostatin M (OM), leukemia inhibitory factor (LIF) or ciliary neurotrophic factor (CNTF) also use the gp130 transducer and induce its heterodimerization with LIF receptor (LIFR). A series of IL-6 mutants have been generated which function as IL-6 receptor antagonists (IL-6RA). These IL-6RA carried substitutions that increased their affinity with IL-6R and abolished 1 or the 2 sites of interaction with gp130. All the IL-6RA inhibited wild-type IL-6. The IL-6RA with one mutated binding site to gp130 inhibited IL-11 activity. They did not affect those of CNTF, LIF and OM, even when used at a very high concentration at which virtually all membrane IL-6R were bound to IL-6RA. IL-6RA with two mutated gp130 binding sites did not affect IL-11, CNTF, LIF or OM activities. The results indicate that the interaction of one gp130 chain with IL-6R/IL-6R complexes inhibited further the dimerization of gp130 induced by IL-11/IL-11R but not its heterodimerization with LIFR. Thus these IL-6RA can also function as IL-11 antagonists.

Original languageEnglish
Pages (from-to)51-56
Number of pages6
JournalEuropean Cytokine Network
Volume8
Issue number1
Publication statusPublished - 1997

Fingerprint

Interleukin-11
Interleukin-6 Receptors
Bioactivity
Oncostatin M
Interleukin-6
Ciliary Neurotrophic Factor
Leukemia Inhibitory Factor
OSM-LIF Receptors
Dimerization
Binding Sites
Signal transduction
Transducers
Signal Transduction
Substitution reactions
Cytokines
Membranes

Keywords

  • Ciliary neurotrophic factor
  • Interleukin-11
  • Interleukin-6
  • Leukemia inhibitory factor
  • Multiple myeloma
  • Oncostatin M

ASJC Scopus subject areas

  • Cell Biology
  • Immunology

Cite this

Ren-Xiao, S., Gennaro, C., Rocco, S., Zong-Jiang, G., & Bernard, K. . (1997). Interleukin-6 receptor antagonists inhibit interleukin-11 biological activity. European Cytokine Network, 8(1), 51-56.

Interleukin-6 receptor antagonists inhibit interleukin-11 biological activity. / Ren-Xiao, Sun; Gennaro, Ciliberto; Rocco, Savino; Zong-Jiang, Gu; Bernard, Klein .

In: European Cytokine Network, Vol. 8, No. 1, 1997, p. 51-56.

Research output: Contribution to journalArticle

Ren-Xiao, S, Gennaro, C, Rocco, S, Zong-Jiang, G & Bernard, K 1997, 'Interleukin-6 receptor antagonists inhibit interleukin-11 biological activity', European Cytokine Network, vol. 8, no. 1, pp. 51-56.
Ren-Xiao, Sun ; Gennaro, Ciliberto ; Rocco, Savino ; Zong-Jiang, Gu ; Bernard, Klein . / Interleukin-6 receptor antagonists inhibit interleukin-11 biological activity. In: European Cytokine Network. 1997 ; Vol. 8, No. 1. pp. 51-56.
@article{806758490b58427cb6b57d0152fee940,
title = "Interleukin-6 receptor antagonists inhibit interleukin-11 biological activity",
abstract = "The IL-6 receptor system comprises two functionally different chains: a binding chain (IL-6R) and a signal-transducing chain (gp130). The IL-6/IL-6R complexes associate with gp130, induce its dimerization and signal transduction. When IL-6 is complexed to IL-6R, two distinct sites of IL-6 are able to bind gp130. Other cytokines - oncostatin M (OM), leukemia inhibitory factor (LIF) or ciliary neurotrophic factor (CNTF) also use the gp130 transducer and induce its heterodimerization with LIF receptor (LIFR). A series of IL-6 mutants have been generated which function as IL-6 receptor antagonists (IL-6RA). These IL-6RA carried substitutions that increased their affinity with IL-6R and abolished 1 or the 2 sites of interaction with gp130. All the IL-6RA inhibited wild-type IL-6. The IL-6RA with one mutated binding site to gp130 inhibited IL-11 activity. They did not affect those of CNTF, LIF and OM, even when used at a very high concentration at which virtually all membrane IL-6R were bound to IL-6RA. IL-6RA with two mutated gp130 binding sites did not affect IL-11, CNTF, LIF or OM activities. The results indicate that the interaction of one gp130 chain with IL-6R/IL-6R complexes inhibited further the dimerization of gp130 induced by IL-11/IL-11R but not its heterodimerization with LIFR. Thus these IL-6RA can also function as IL-11 antagonists.",
keywords = "Ciliary neurotrophic factor, Interleukin-11, Interleukin-6, Leukemia inhibitory factor, Multiple myeloma, Oncostatin M",
author = "Sun Ren-Xiao and Ciliberto Gennaro and Savino Rocco and Gu Zong-Jiang and Bernard, {Klein .}",
year = "1997",
language = "English",
volume = "8",
pages = "51--56",
journal = "Environmental and Molecular Mutagenesis",
issn = "0893-6692",
publisher = "John Libbey Eurotext",
number = "1",

}

TY - JOUR

T1 - Interleukin-6 receptor antagonists inhibit interleukin-11 biological activity

AU - Ren-Xiao, Sun

AU - Gennaro, Ciliberto

AU - Rocco, Savino

AU - Zong-Jiang, Gu

AU - Bernard, Klein .

PY - 1997

Y1 - 1997

N2 - The IL-6 receptor system comprises two functionally different chains: a binding chain (IL-6R) and a signal-transducing chain (gp130). The IL-6/IL-6R complexes associate with gp130, induce its dimerization and signal transduction. When IL-6 is complexed to IL-6R, two distinct sites of IL-6 are able to bind gp130. Other cytokines - oncostatin M (OM), leukemia inhibitory factor (LIF) or ciliary neurotrophic factor (CNTF) also use the gp130 transducer and induce its heterodimerization with LIF receptor (LIFR). A series of IL-6 mutants have been generated which function as IL-6 receptor antagonists (IL-6RA). These IL-6RA carried substitutions that increased their affinity with IL-6R and abolished 1 or the 2 sites of interaction with gp130. All the IL-6RA inhibited wild-type IL-6. The IL-6RA with one mutated binding site to gp130 inhibited IL-11 activity. They did not affect those of CNTF, LIF and OM, even when used at a very high concentration at which virtually all membrane IL-6R were bound to IL-6RA. IL-6RA with two mutated gp130 binding sites did not affect IL-11, CNTF, LIF or OM activities. The results indicate that the interaction of one gp130 chain with IL-6R/IL-6R complexes inhibited further the dimerization of gp130 induced by IL-11/IL-11R but not its heterodimerization with LIFR. Thus these IL-6RA can also function as IL-11 antagonists.

AB - The IL-6 receptor system comprises two functionally different chains: a binding chain (IL-6R) and a signal-transducing chain (gp130). The IL-6/IL-6R complexes associate with gp130, induce its dimerization and signal transduction. When IL-6 is complexed to IL-6R, two distinct sites of IL-6 are able to bind gp130. Other cytokines - oncostatin M (OM), leukemia inhibitory factor (LIF) or ciliary neurotrophic factor (CNTF) also use the gp130 transducer and induce its heterodimerization with LIF receptor (LIFR). A series of IL-6 mutants have been generated which function as IL-6 receptor antagonists (IL-6RA). These IL-6RA carried substitutions that increased their affinity with IL-6R and abolished 1 or the 2 sites of interaction with gp130. All the IL-6RA inhibited wild-type IL-6. The IL-6RA with one mutated binding site to gp130 inhibited IL-11 activity. They did not affect those of CNTF, LIF and OM, even when used at a very high concentration at which virtually all membrane IL-6R were bound to IL-6RA. IL-6RA with two mutated gp130 binding sites did not affect IL-11, CNTF, LIF or OM activities. The results indicate that the interaction of one gp130 chain with IL-6R/IL-6R complexes inhibited further the dimerization of gp130 induced by IL-11/IL-11R but not its heterodimerization with LIFR. Thus these IL-6RA can also function as IL-11 antagonists.

KW - Ciliary neurotrophic factor

KW - Interleukin-11

KW - Interleukin-6

KW - Leukemia inhibitory factor

KW - Multiple myeloma

KW - Oncostatin M

UR - http://www.scopus.com/inward/record.url?scp=0030888086&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030888086&partnerID=8YFLogxK

M3 - Article

VL - 8

SP - 51

EP - 56

JO - Environmental and Molecular Mutagenesis

JF - Environmental and Molecular Mutagenesis

SN - 0893-6692

IS - 1

ER -